Share Twitter LinkedIn Facebook Email Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib. Advertisement
Edetek’s CONFORM Platform: Streamlining Clinical Data Management in Oncology Trials General 3 Mins Read